Reliable Data You Can Trust
Reliable Data You Can Trust
By Infinium Global Research Aug, 2020
The Global Non-hodgkin Lymphoma Treatment Market is expected to grow at a CAGR of 7.20% between 2019 and 2025 in terms of
value. The growing prevalence of non-Hodgkin lymphoma cancers are driving the
growth of the non-Hodgkin lymphoma treatment market. The American Cancer Society
estimates that 74,200 cases of non-Hodgkin lymphoma will be diagnosed in 2019.
Furthermore, rapidly expanding elderly population is anticipated to boost the
market growth as majority of patients with non-Hodgkin lymphoma are over the
age of 60. In addition, growing number of clinical trials for the development
of new drugs and the launch of several novel drugs for the treatment of
non-Hodgkin lymphoma are anticipated to propel the growth of the non-Hodgkin
lymphoma treatment market. Several major
manufacturers are focusing on the development of new products for the treatment
of Non-Hodgkin lymphoma (NHL), which in turn will boost the market growth over
the forecast period. However, high cost associated with the treatment of
non-Hodgkin lymphoma is likely to hamper the growth of the non-Hodgkin lymphoma
treatment market. In addition, expiry of several standard drugs are expected to
create lucrative opportunities for the emerging market players in the
non-Hodgkin lymphoma treatment market.
The incidence of non-Hodgkin lymphoma (NHL)
varies by geographic region. The areas with the highest incidence of NHL are
North America, Europe, and Australasia, as well as several countries in Africa
and South America. North America accounts for the largest revenue in the global
non-Hodgkin lymphoma treatment market. The high prevalence of non- Hodgkin
lymphoma contributes to the growth of the market. The disease accounts for 4%
of all cancers in the United States. Furthermore, well established healthcare
infrastructure, favorable reimbursement policies and high spending capacity of
the people in North American countries such as the U.S. and Canada favors the
growth of the market in this region. Europe is anticipated to hold the second
largest share in the total addressable market owing to factors such as
increasing cases of B-Cell lymphoma, rising aging population and growing number
in the clinical trials for the treatment of NHL treatment market in this
region.